Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04407234 · ClinicalTrials.gov registry record · Phase 1
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04407234 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT04407234, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.
Interventions
- DRUG Acetaminophen
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2021-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04407234
The ClinicalTrials.gov registry entry for NCT04407234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acetaminophen is the first listed.
NCT04407234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04407234 about?
NCT04407234 is a clinical study titled "A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide". The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.
What is the current status of trial NCT04407234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-09-15. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT04407234?
The interventions under investigation include: Acetaminophen (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT04407234?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.